The primary purpose of this study is to describe renal anemia treatment patterns in non-dialysis dependent (ND) and dialysis dependent (DD) populations, with a particular focus on iron use in erythropoiesis stimulating agent (ESA) treated patients. This study will also provide an epidemiological description of chronic kidney disease (CKD) associated anemia in relation to CKD stage, dialysis modality and underlying morbidity, as well as describe the relationship between inflammation and ESA treatment and describe the associated cardiovascular illness in ESA treated patients.
Data from year 2015 will be used for the prevalence analysis.The prevalent population of CKD patients \> 18 years in the Swedish Renal Registry in 2015 both dependent on dialysis (DD) and not on dialysis (ND).
Study Type
OBSERVATIONAL
Enrollment
14,415
Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
SE46001
Stockholm, Sweden
Iron use in erythropoiesis stimulating agent (ESA) treated patients in the prevalent non-dialysis dependent (ND) population
Route of administration of iron (oral, intravenous (IV), or no iron use) over the source period.
Time frame: 1 year (data from 2015)
Iron use in ESA treated patients in the prevalent dialysis dependent (DD) population
Route of administration of iron (oral, intravenous (IV), or no iron use) over the source period.
Time frame: 1 year (data from 2015)
Proportion of non-dialysis dependent (ND) patients on low, normal, high dose erythropoiesis stimulating agent (ESA)
The proportion of ND patients on low, normal and high dose ESA will be calculated.
Time frame: 1 year (data from 2015)
Proportion of dialysis dependent (DD) patients on low, normal, high dose ESA
The proportion of DD patients on low, normal and high dose ESA will be calculated.
Time frame: 1 year (data from 2015)
ESA use in ND patients at each CKD stage
The number of ND patients using/not using ESA at each CKD stage.
Time frame: 1 year (data from 2015)
ESA use in DD patients
The number of DD patients using/not using ESA.
Time frame: 1 year (data from 2015)
Proportion of ND patients treated with ESAs at each chronic kidney disease (CKD) stage with or without oral/IV iron
Proportion of ND patients treated with ESAs in each CKD stage with or without oral/iv iron.
Time frame: 1 year (data from 2015)
Proportion of DD patients treated with ESAs at each chronic kidney disease (CKD) stage with or without oral/IV iron
Proportion of DD patients treated with ESAs in each CKD stage with or without oral/iv iron.
Time frame: 1 year (data from 2015)
Proportion of ESA treated ND patients within Haemoglobin (Hb) levels within pre-specified target range
Proportion of ND patients within pre-specified Hb target.
Time frame: 1 year (data from 2015)
Proportion of ESA treated DD patients within Haemoglobin (Hb) levels within pre-specified target range
Proportion of DD patients within pre-specified Hb target.
Time frame: 1 year (data from 2015)
Proportion of ND patients with anemia who are not treated with ESAs
Proportion of ND patients with anemia not treated with ESAs.
Time frame: 1 year (data from 2015)
Proportion of DD patients with anemia who are not treated with ESAs
Proportion of DD patients with anemia not treated with ESAs.
Time frame: 1 year (data from 2015)
Proportion of ESA treated ND patients with low or medium and high C-reactive protein (CRP)
Proportion of ND patients with low, medium or high CRP.
Time frame: 1 year (data from 2015)
Proportion of ESA treated DD patients with low or medium and high CRP
Proportion of DD patients with low, medium or high CRP.
Time frame: 1 year (data from 2015)
Proportion of ESA treated ND patients with hyperlipidemia (HDL/LDL) and/or taking lipid lowering preparations
Proportion of ESA treated ND patients with hyperlipidemia High density lipoprotein / Low density lipoprotein (HDL/LDL) and/or taking lipid lowering drugs.
Time frame: 1 year (data from 2015)
Proportion of ESA treated DD patients with hyperlipidemia (HDL/LDL) and/or taking lipid lowering preparations
Proportion of ESA treated DD patients with hyperlipidemia (HDL/LDL) and/or taking lipid lowering drugs.
Time frame: 1 year (data from 2015)
Proportion of ESA treated ND patients with high blood pressure and/or taking anti-hypertensive medication
Proportion of ESA treated ND patients with high blood pressure and/or taking anti-hypertensive drugs.
Time frame: 1 year (data from 2015)
Proportion of ESA treated DD patients with high blood pressure and/or taking anti-hypertensive medication
Proportion of ESA treated DD patients with high blood pressure and/or taking anti-hypertensive drugs.
Time frame: 1 year (data from 2015)
Number of ND patients with serious cardiovascular events
The number of ND patients with serious cardiovascular events (i.e., myocardial infarction, heart failure, myocardial ischemia) will be evaluated.
Time frame: 4 years (CV events may be compared from data covering 2012 to 2016)
Number of DD patients with serious cardiovascular events
The number of DD patients with serious cardiovascular events (i.e., myocardial infarction, heart failure, myocardial ischemia) will be evaluated.
Time frame: 4 years (CV events may be compared from data covering 2012 to 2016)
Number of ND patients with serious thromboembolic events
The number of ND patients with serious thromboembolic events (i.e. stroke) will be evaluated.
Time frame: 1 year (data from 2015)
Number of DD patients with serious thromboembolic events
The number of DD patients with serious thromboembolic events (i.e. stroke) will be evaluated.
Time frame: 1 year (data from 2015)
All cause mortality: ND
The number of deaths in the ND population.
Time frame: 1 year (data from 2015)
All cause mortality: DD
The number of deaths in the DD population.
Time frame: 1 year (data from 2015)
Correlation between ESA dose and Hb level in relation to CKD severity (stage 3,4, 5 and DD)
Scatter plots of ESA dose against hemoglobin level for CKD severity (stage 3, 4, 5 and DD).
Time frame: 1 year (data from 2015)
Correlation between Haemoglobin (Hb) level and CKD severity: ND
Box plots of ESA dose against CKD severity (stage 3,4, 5).
Time frame: 1 year (data from 2015)
Correlation between ESA dose and C-reactive protein (CRP) level: ND
Scatter plot of ESA dose versus CRP level in ND population.
Time frame: 1 year (data from 2015)
Correlation between ESA dose and CRP level: DD
Scatter plot of ESA dose versus CRP level in DD population.
Time frame: 1 year (data from 2015)
Relationship between ESA dose and occurrence of Cardiovascular (CV) events in ND population
Box plot of ESA dose in ND patients with or without CV events.
Time frame: 1 year (data from 2015)
Relationship between Hb level and occurrence of CV events in ND population
Box plot of Hb level in ND patients with or without CV events.
Time frame: 1 year (data from 2015)
Relationship between Hb level and occurrence of CV events in DD population
Box plot of Hb level in DD patients with or without CV events.
Time frame: 1 year (data from 2015)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.